Lobbying Relationship

Client

Johnson & Johnson Services, Inc.

More records

Lobbying firm

COVINGTON & BURLING LLP

More records

  • OTC drugs, cosmetics and self-care in general, including issues around drug shortages, PAHPA re-authorization, implementation of MOCRA and dietary supplement reform. (Lobbying activity conducted on behalf of Kenvue Inc.; see line 25)

Duration: to

General Issues: Health Issues

Spending: about $1,300,000 (But it's complicated. Here's why.)

Agencies lobbied since 2008: House of Representatives, U.S. Senate

Bills mentioned

S.1113: Personal Care Products Safety Act

Sponsor: Dianne Feinstein (D-Calif.)

S.2003: FDA Cosmetic Safety and Modernization Act

Sponsor: Orrin G. Hatch (R-Utah)

S.2315: Over-the-Counter Drug Safety, Innovation, and Reform Act

Sponsor: Johnny Isakson (R-Ga.)

H.R.5333: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018

Sponsor: Robert E. Latta (R-Ohio)

S.726: Personal Care Products Safety Act

Sponsor: Dianne Feinstein (D-Calif.)

H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1816: Children’s Product Warning Label Act of 2019

Sponsor: Debbie Dingell (D-Mich.)

H.R.5279: Cosmetic Safety Enhancement Act of 2019

Sponsor: Frank Pallone (D-N.J.)

S.2100: Personal Care Products Safety Act

Sponsor: Dianne Feinstein (D-Calif.)

S.4338: Increasing Transparency in Generic Drug Applications Act

Sponsor: Margaret Hassan (D-N.H.)

H.R.7667: Food and Drug Amendments of 2022

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.2617: Consolidated Appropriations Act, 2023

Sponsor: Gerald E. Connolly (D-Va.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Richard F. Kingham Partner
Erika K. Lietzan Partner
Jeffrey B. Elikan Partner
Wade Ackerman Sr. FDA Counsel, US Senate Committee on Health, Education, Labor & Pensions
Erika Lietzan Partner
Gary Heimberg n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Amendment
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Registration
Q3 Report
Termination
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q2 Report
Q1 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page